Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy

BACKGROUND: Estimates of detectable antinuclear antibodies (ANA) prevalence vary widely, from 6% in healthy populations to 50–80% in patients with autoimmune disease. However, there is a lack of evidence about the overall prevalence in inflammatory bowel disease (IBD) and ANA seroconversion after th...

Descripción completa

Detalles Bibliográficos
Autores principales: García, María José, Rodríguez-Duque, Juan Carlos, Pascual, Marta, Rivas, Coral, Castro, Beatriz, Raso, Sandra, López-Hoyos, Marcos, Arias-Loste, María Teresa, Rivero, Montserrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894967/
https://www.ncbi.nlm.nih.gov/pubmed/35251307
http://dx.doi.org/10.1177/17562848221077837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894967/
https://www.ncbi.nlm.nih.gov/pubmed/35251307
http://dx.doi.org/10.1177/17562848221077837

Ejemplares similares